Genentech, Inc. – Hemophilia A

Submitted By:
Published Date:
January 25, 2020

Access Program Information

This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab
to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is
commercially available in the United States for the indication of hemophilia A with FVIII
inhibitors. Discontinuation may occur earlier if participant or physician decides to
discontinue treatment or the sponsor discontinues emicizumab clinical development.

Rare Disease:
Hemophilia A